# Economic Plan

# This document identifies the areas prioritised for economic modelling. The final analysis may differ from those described below. The rationale for any differences will be explained in the guideline.

# Guideline

Spondyloarthritis: the diagnosis and management of spondyloarthritis (Spondyloarthritis)

# List of Modelling Questions

|  |  |
| --- | --- |
| **Clinical questions by scope area** | **Scope areas:**  4.3.1 a) Early recognition (signs and symptoms, risk factors).  4.3.1 c) Initial assessment (including case-finding in people with a comorbid condition, risk factors, signs and symptoms, blood tests and imaging).  **Review questions:**  RQ1 What signs and symptoms should prompt a healthcare professional to think of spondyloarthritis?  RQ2 What risk factors should increase suspicion of spondyloarthritis?  RQ6 What is the comparative effectiveness of different referral strategies in diagnosing spondyloarthritis?  RQ7 What is the diagnostic utility of a HLA B27 test for investigating suspected spondyloarthritis?  RQ8 What is the diagnostic utility of an erythrocyte sedimentation rate test for investigating suspected spondyloarthritis?  RQ9 What is the diagnostic utility of a C-reactive protein test for investigating suspected spondyloarthritis?  RQ10 What is the diagnostic utility of imaging (alone or in sequence) for investigating suspected spondyloarthritis?  RQ12 What are the indications (signs, risk factors, test or scan findings) for referral for specialist advice at initial diagnosis? |
| Population | People with chronic back pain (duration ≥3 months; onset at age ≤45) at first presentation to healthcare services |
| Interventions considered for inclusion | Various referral criteria to identify people with axial spondyloarthritis |
| Type of analysis | Lifetime cost–utility analysis |